Are PD-1 antibodies safe for use in metastatic uveal melanoma?

Abstract

prospective data support similar findings: 0 of 53 patients had objective response, 2-year OS rate was 7% and safety data showed 16 patients (30%) with grade 1–2 AEs and 19 patients (36%) with grade 3–4 AEs [25] . Grade 3–4 AEs were diarrhea, colitis and transaminitis. There was one possible treatment-related death in the setting of pancytopenia with subsequent cerebral hemorrhage and respiratory insufficiency. An abstract from a second Phase II study of ipilimumab 10 mg/kg (EudraCT 2010–024415–4) in 32 patients reported 15 patients (47%) with grade 3–4 AEs (abdominal pain, hypophysitis, emesis, diarrhea, asthenia, proctalgia, bone pain, urinary tract infection, hepatotoxicity, multi-organ failure, altered state of consciousness and vascular compression) [26] . Responses were similarly modest, with one partial response and six patients with stable disease at a median follow-up of 5.5 months.